MDxHealth (0O8G) Share Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0O8G Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

MDxHealth

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0O8G Stock 12 Month Forecast

Average Price Target

€1.29

▼(-57.31% Downside)

Based on 3 Wall Street analysts offering 12 month price targets for MDxHealth in the last 3 months. The average price target is €1.29 with a high forecast of €1.72 and a low forecast of €0.86. The average price target represents a -57.31% change from the last price of €3.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","-1":"-€1","0.25":"€0.25","1.5":"€1.5","2.75":"€2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.71912136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.28934102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.85956068,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.019,2.9190093353846156,2.819018670769231,2.719028006153846,2.6190373415384616,2.519046676923077,2.4190560123076925,2.319065347692308,2.219074683076923,2.1190840184615385,2.019093353846154,1.9191026892307692,1.8191120246153847,{"y":1.71912136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.019,2.8859493092307695,2.7528986184615385,2.619847927692308,2.486797236923077,2.3537465461538463,2.2206958553846157,2.0876451646153846,1.9545944738461538,1.821543783076923,1.6884930923076922,1.5554424015384614,1.4223917107692308,{"y":1.28934102,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.019,2.852889283076923,2.6867785661538464,2.5206678492307693,2.3545571323076926,2.1884464153846155,2.0223356984615384,1.8562249815384615,1.6901142646153846,1.5240035476923077,1.3578928307692308,1.1917821138461537,1.0256713969230769,{"y":0.85956068,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.019,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.019,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1.72

Average Price Target€1.29

Lowest Price Target€0.86

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mark Massaro

BTIG

€3.44→€1.72

Buy

-43.08%

Downside

Reiterated

08/21/26

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), Revolution Medicines (NASDAQ: RVMD) and MDxHealth (NASDAQ: MDXH)

Matt Larew

William Blair

―

Hold

―

Reiterated

08/14/26

Analysts Offer Insights on Healthcare Companies: MDxHealth (NASDAQ: MDXH), Opko Health (NASDAQ: OPK) and Zenas BioPharma, Inc. (NASDAQ: ZBIO)

Daniel Brennan

TD Cowen

€0.86

Buy

-71.54%

Downside

Reiterated

08/13/26

MDxHealth Earns Buy Rating on Strengthened Balance Sheet, Improved Margins, and Reaffirmed 2026 Growth and Profitability Targets

William Bonello

Craig-Hallum

€2.58

Buy

-14.61%

Downside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (NASDAQ: TYRA) and MDxHealth (NASDAQ: MDXH)

Thomas Flaten

Lake Street

€7.74→€4.3

Buy

42.31%

Upside

Reiterated

05/14/26

MDxHealth price target lowered to $5 from $9 at Lake StreetMDxHealth price target lowered to $5 from $9 at Lake Street

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mark Massaro

BTIG

€3.44→€1.72

Buy

-43.08%

Downside

Reiterated

08/21/26

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY), Revolution Medicines (NASDAQ: RVMD) and MDxHealth (NASDAQ: MDXH)

Matt Larew

William Blair

―

Hold

―

Reiterated

08/14/26

Analysts Offer Insights on Healthcare Companies: MDxHealth (NASDAQ: MDXH), Opko Health (NASDAQ: OPK) and Zenas BioPharma, Inc. (NASDAQ: ZBIO)

Daniel Brennan

TD Cowen

€0.86

Buy

-71.54%

Downside

Reiterated

08/13/26

MDxHealth Earns Buy Rating on Strengthened Balance Sheet, Improved Margins, and Reaffirmed 2026 Growth and Profitability Targets

William Bonello

Craig-Hallum

€2.58

Buy

-14.61%

Downside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (NASDAQ: TYRA) and MDxHealth (NASDAQ: MDXH)

Thomas Flaten

Lake Street

€7.74→€4.3

Buy

42.31%

Upside

Reiterated

05/14/26

MDxHealth price target lowered to $5 from $9 at Lake StreetMDxHealth price target lowered to $5 from $9 at Lake Street

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARDXArdelyx

ZVRAZevra Therapeutics

HROWHarrow Health

KURAKura Oncology

SNDXSyndax Pharmaceuticals

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MDxHealth

3 Months

Daniel BrennanTD Cowen

Success Rate

5/12 ratings generated profit

Average Return

+9.07%

Copying Daniel Brennan's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +9.07% per trade.

1 Year

Thomas FlatenLake Street

Success Rate

5/12 ratings generated profit

Average Return

-1.06%

Copying Thomas Flaten's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -1.06% per trade.

2 Years

Daniel BrennanTD Cowen

Success Rate

3/12 ratings generated profit

Average Return

-38.09%

Copying Daniel Brennan's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -38.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0O8G Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0O8G has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0O8G average Analyst price target in the past 3 months is 1.29.

Each month's total comprises the sum of three months' worth of ratings.

0O8G Financial Forecast

0O8G Earnings Forecast

Next quarter’s earnings estimate for 0O8G is -€0.08 with a range of -€0.09 to -€0.05. The previous quarter’s EPS was -€0.15. 0O8G beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0O8G has Performed in-line its overall industry.

0O8G Sales Forecast

Next quarter’s sales forecast for 0O8G is €24.32M with a range of €22.79M to €25.11M. The previous quarter’s sales results were €23.32M. 0O8G beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0O8G has Performed in-line its overall industry.

0O8G Stock Forecast FAQ

What is GB:0O8G’s average 12-month price target, according to analysts?

Based on analyst ratings, MDxHealth’s 12-month average price target is 1.29.

What is GB:0O8G’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0O8G, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDxHealth a Buy, Sell or Hold?

MDxHealth has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is MDxHealth’s share price target?

The average share price target for MDxHealth is 1.29. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1.72 ,and the lowest forecast is €0.86. The average share price target represents -57.31% Decrease from the current price of €3.02.

What do analysts say about MDxHealth?

MDxHealth’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of MDxHealth?

To buy shares of GB:0O8G, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

MDxHealth (0O8G) Share Forecast & Price Target

0O8G Analyst Ratings

0O8G Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MDxHealth

0O8G Analyst Recommendation Trends

0O8G Financial Forecast

0O8G Earnings Forecast

0O8G Sales Forecast

0O8G Stock Forecast FAQ

Detailed List of Analyst Forecasts